Veriheal

JANUARY 26, 2023

Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. Most commonly, pharmaceutical medication is prescribed to regulate moods. But there may be some good news for those coping with this mental health issue.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

The Joint Blog

DECEMBER 20, 2020

According to the study, respondents were most likely to report marijuana use for pain relief, improved sleep and to deal with nausea. “Respondents reported a median score of 90 on a zero to 100-point scale in response to the question, “How does cannabis affect your conditions or symptoms overall?”

Sleep 49

Sleep Data Pharmaceutical Marijuana 49

CannaMD

JULY 23, 2020

In the novel study conducted by researchers at the University of New Mexico, nearly 2,000 people self-administered cannabis over a three-year period and reported their marijuana use via the Releaf App that was specifically designed for the study’s data collection needs. Human reports to date on the subject are largely anecdotal.

Data 89

Data Chronic Pain Sleep Patients 89

SpeedWeed

MARCH 13, 2021

Less well-known symptoms include sleep disorders , cognitive changes, pain, anxiety, depression , and hallucinations. Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. After analyzing the data, the researchers found that 24.5%

Patients 52

Patients Treatment Therapy Sleep 52

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

JUNE 7, 2021

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. As the disease progresses, individuals may suffer from loss of memory and dementia.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Cannabis Law Report

SEPTEMBER 14, 2021

Those insights will help bring products to market that are specifically formulated based on rigorous evidence to address need states like chronic pain, restful sleep, and general health and well-being. Step four: Brands select packaging, labels and other physical concepts for the selected product in a fully customizable experience.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

The Cannigma

JUNE 15, 2021

However, the scientific data on CBG is nowhere near as developed as what we have on CBD. The vast majority of what we know about CBD’s medicinal effects is based on laboratory studies, is far from being properly understood, and lacks solid scientific data on human subjects — aside from epilepsy 5. Easy access.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Veriheal

OCTOBER 3, 2022

With the growing acceptance and legalization of cannabis, the pharmaceutical industry is taking serious hits, according to a 2022 novel study into the impact of cannabis legalization on pharmaceutical firms. What Is the Pharmaceutical Industry? pharmaceuticals). Still, most pharmaceuticals are heavily processed.

Pharmaceutical 104

Pharmaceutical Patients Research and Development Legalization 104

Cannabis Law Report

AUGUST 16, 2021

It is also a tool used to “determine the nature and scope of child abuse and neglect” and compare Arizona data to national trends, regardless of whether that neglect or abuse arose from the lawful or unlawful use of substances, a mental illness or incapacity, or simply an inability to properly care for a child.

Safety 116

Safety Patients Cannabis Law 116

Kind Meds (Cannabis Education Blog)

FEBRUARY 24, 2022

In reality, people using marijuana during this time may have been self-medicating for a mental condition, choosing to use a different coping mechanism than the pharmaceuticals available at the time, pursuing better sleep, or simply enjoying a nontraditional method of increasing productivity and creativity. Having hand pain?

Marijuana 52

Marijuana Research and Development Sleep Strains 52

Canna Care Docs

JULY 29, 2019

She said it “just barely covers the pain” of her condition. It makes me relax, which in turn slows the shaking down and I can grab some sleep,” she said. Noting her mother’s reduced pain and relief from other pharmaceutical side effects, she said, “I have to say, I’m kind of an advocate for it.” Edelstein said. Gluchacki said.

Chronic Pain 53

Chronic Pain Sleep Education Dispensary 53

Cannabis Info

MARCH 2, 2019

Epilepsy is a neurological condition, that directly affects the nervous system and causes seizures in individuals who suffer from the condition. However, the most common attempt at treating the condition is through medication, many patients may need to take them for the rest of their life. .” WHAT EXACTLY IS EPILEPSY?

Epilepsy 69

Epilepsy Treatment Marijuana Research and Development 69

CannaTech

OCTOBER 14, 2018

Similar conditions in the Imperial Valley of extreme southern California have permitted cultivators like Farmtiva to thrive as the company operates an industrial hemp research and grow facility on 160 acres of a former U.S. billion by 2022, according to New Frontier Data, a premier cannabis data analytics firm. In the U.S.

Hemp 53

Hemp Research and Development Agriculture Seed-To-Sale 53

Veriheal

SEPTEMBER 23, 2021

Veriheal: What are some of the most common conditions you treat with iboga? Levi: The most common conditions we treat are depression, anxiety, PTSD, childhood trauma, and we also treat people who come looking for a reset in life. All human conditions depend on healing physically, mentally, and spiritually.

Treatment 98

Treatment Medicine Research and Development Therapy 98

Cannabis Law Report

SEPTEMBER 2, 2022

The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study. By expanding access and, thus use, legalization could permit cannabis to compete with conventional pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Legalization Marijuana Data 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. Spanagel R, Bilbao A.

CBD 144

CBD Seed-To-Sale Food Access 144

Project CBD

MAY 3, 2023

And it does appear to address some of the main issues that people turn to cannabis for — inflammation, pain, anxiety, sleep problems, depression, and cancer. CannMed: For what conditions do you think CBG has the most promise? It was highly rated for anxiety, pain, depression, and sleep problems.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

JANUARY 9, 2019

Phoenix, headquartered in Denver, distributes medicinal cannabis products around the globe to treat seven major categories of medical conditions including pain, cancer, autoimmune, metabolic, neurological, psychological and sleep disorders. The biggest pushback Phoenix has received until now has been the lack of data, Tindall said.

Therapy 85

Therapy Clinical Trials Treatment Medicine 85

Veriheal

JANUARY 5, 2023

A separate report published by Data Bridge Market research spotlighted the sheer size of the CBD market. The cannabinoid is being utilized for a broad spectrum of medical problems, such as chronic pain, stress, anxiety, sleep/insomnia, skin care, migraine, seizures, neurological conditions, and inflammation.

Clinical Trials 96

Clinical Trials Safety Consumption CBD 96

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. We also used manifest textual analysis to search for word frequencies, and specific conditions referred to in the articles retrieved. At the same time, the outlook on cannabis research data is largely positive.

Research and Development 52

Research and Development Medicine Access Media 52

SMPL

MAY 26, 2020

And because CBD doesn’t get you high, it was easy to miss; hardly anyone outside of pharmaceutical companies and academia had heard of it. In the fall of 2010, a Project CBD website was set up where anyone could look through studies organized by disease or condition. A few months later, the network of early CBD advocates met up at Ms.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

The Cannigma

NOVEMBER 23, 2021

The app helps patients make sense of their journey by simplifying the information and supplying data-driven insights into their regimen and its effects. We delve into how data can further our understanding of different types of cannabis and why standardization is desperately needed in the industry. 0:14:10.3]

Data 52

Data Patients Access Wellness and Beauty 52

CannaTech

FEBRUARY 25, 2019

Kanabo’s proprietary medical cannabis extracts focus on sleep disorders and post-traumatic stress disorder, and are specially formulated for vaporization with the medically certified VapePod vaporizer platform. Indorz : Indoor cannabis farming data solution that predicts, analyzes, and automates the grow process to maximize yield and quality.

Research and Development 85

Research and Development Hybrid Treatment Strains 85

The Cannigma

DECEMBER 22, 2021

Listen & Subscribe: Israel is world-renowned for the research and innovation that is taking place there, and unofficial data suggests that around 20% of the Israeli population uses cannabis. At the moment, you said that they could potentially add more conditions. IR: Well, today, there is a closed list, basically, of conditions.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Green Relief

MAY 13, 2018

Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. These plant cannabinoids were also deemed useful for treating other neurodegenerative conditions, “such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”. CBD for CTE. Nutritional supplements and antioxidants.

THC 64

THC CBD Cannabinoids Research and Development 64

Green Relief

MAY 12, 2018

Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. These plant cannabinoids were also deemed useful for treating other neurodegenerative conditions, “such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”. CBD for CTE. Nutritional supplements and antioxidants.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

OCTOBER 12, 2021

Diamandis joins Radicle Science as the healthtech company accelerates growth with industry veteran Sheldon Borkin PhD as CTO, the launch of a first of its kind real-world sleep study, and updates on significant milestones this year. Radicle Real World Sleep results will be announced in early 2022. “We

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

DECEMBER 7, 2021

The four-week Institutional Review Board (IRB) approved randomized controlled trial (RCT) of nearly 3,000 participants assigned to different botanical products containing CBD revealed significant improvement across all five health outcomes studied: well-being, quality of life, longer-term pain, feelings of anxiety, and sleep quality.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

JUNE 4, 2021

David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. Jonathan is the CEO and founder of Gilgamesh Pharmaceuticals. in/carhart-harris-robin-19112542/ [link]. David Nutt. Drug Science. Matthew Johnson.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

AUGUST 24, 2019

Physicians : Approximately 2,300 Florida Medics who recommend cannabis as treatment for a wide variety of conditions and symptoms. ” This data gives a glimpse into Florida’s best future: “The legal cannabis industry employed a total of 1,290 people in Florida at the beginning of 2018, so that was a growth rate of 703%.

Banking 49

Banking Marijuana Media Patients 49

Cannabis Law Report

SEPTEMBER 22, 2019

Our findings match many of the sales data reported by various outlets, showing medical cannabis sales shrink after adult-use legalization, while recreational or adult-use sales drive the market: Over a quarter of medical users reported that they were using more often than before adult-use legalization. ’ . .”

Cannabis 45

Cannabis Access Patients Legalization 45

The Cannigma

JANUARY 19, 2022

We think now that as more and more data is becoming available, the cannabis could be a very useful treatment both THC and CBD have shown promise in helping with the inflammation and some of the damage that has occurred in the brain. I mean, asking questions was like, how can I function, how can I sleep, how can I not be in pain.

Patients 83

Patients Compliance Compliance Cannabis 83

Cannabis Law Report

JULY 30, 2019

Patients carefully consider a choice of cannabis physician based on their personal past health, their qualifying condition, and their current health needs: essentially, patients decide which physician can serve that patient’s needs by adding cannabis as a therapeutic medication. . ” .

Marijuana 45

Marijuana Patients Research and Development Programs 45

Cannabis Law Report

MAY 14, 2022

Based upon the significant public concern for safety and lack of scientific and public health data related to the conversion process, the state’s Cannabis Regulatory Agency withdrew the proposed rulemaking. MI – Michigan cannabis regulators axed a plan to allow hemp to be synthetically converted to THC.

Banking 52

Banking Recreational Research and Development Cannabis 52